ストックスクリーナーアプリを入手
38.75
0.68%
0.26
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years - Yahoo Finance
Protagonist Therapeutics, Inc SEC 10-K Report - TradingView
Hussman Strategic Advisors Inc. Purchases New Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics: Q4 Earnings Snapshot - The Advocate
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M - Marketscreener.com
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98 -February 21, 2025 at 07:14 am EST - Marketscreener.com
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - ACCESS Newswire
AlphaCentric Advisors LLC Decreases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics CEO Dinesh Patel sells shares worth $204,606 By Investing.com - Investing.com Australia
Protagonist Therapeutics (PTGX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Stocks Generating Improved Relative Strength: Protagonist Therapeutics - MSN
Protagonist Therapeutics CEO Dinesh Patel sells shares worth $204,606 - Investing.com India
Protagonist Therapeutics CEO Sells Shares to Cover Tax Obligation - TradingView
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
(PTGX) Proactive Strategies - Stock Traders Daily
Louisiana State Employees Retirement System Acquires 300 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Australia
Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Nigeria
Jefferies maintains Buy on Protagonist Therapeutics, $57 target - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Yousif Capital Management LLC - Defense World
Will Weakness in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Prove Temporary Given Strong Fundamentals? - Simply Wall St
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) PT at $56.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now - Insider Monkey
Bleakley Financial Group LLC Has $246,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $56.00 Average PT from Brokerages - Defense World
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Protagonist Therapeutics' (PTGX) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News
HC Wainwright Reaffirms "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Polycythemia Vera Market Predicted to See Upsurge Through 2034, - openPR
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reiterated at HC Wainwright - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - ETF Daily News
Protagonist Therapeutics’ (PTGX) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Given Market Outperform Rating at JMP Securities - Armenian Reporter
Objective long/short (PTGX) Report - Stock Traders Daily
Truist maintains Buy on Protagonist Therapeutics with $60 target - MSN
Truist maintains Buy on Protagonist Therapeutics with $60 target By Investing.com - Investing.com UK
JMP Securities maintains PTGX stock with $58 target - MSN
Caprock Group LLC Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Selling Buzz: Protagonist Therapeutics Inc [PTGX] Chief Medical Officer MOLINA ARTURO MD sells 26,000 shares of the company – Knox Daily - Knox Daily
Financial Metrics Check: Protagonist Therapeutics Inc (PTGX)’s Ratios for Trailing Twelve Months - The Dwinnex
Protagonist Therapeutics Inc (PTGX) deserves closer scrutiny - US Post News
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $53.00 - MarketBeat
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Increased by Nisa Investment Advisors LLC - Defense World
Top Cancer Experts to Review Game-Changing Blood Disorder TreatmentHere's What's Coming - StockTitan
Protagonist Receives $34 Million from Warrant Exercises - ACCESS Newswire
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):